Duplexed parvovirus vectors
View Patent ↗The present invention provides duplexed parvovirus vector genomes that are capable under appropriate conditions of forming a double-stranded molecule by intrastrand base-pairing. Also provided are duplexed parvovirus particles comprising the vector genome. Further disclosed are templates and methods for producing the duplexed vector genomes and duplexed parvovirus particles of the invention. Methods of administering these reagents to a cell or subject are also described. Preferably, the parvovirus capsid is an AAV capsid. It is further preferred that the vector genome comprises AAV terminal repeat sequences.
1. A method of administering a nucleic acid to a mammalian subject comprising administering to the mammalian subject a cell that has been contacted with a parvovirus particle comprising a vector genome under conditions sufficient for the parvovirus particle vector genome to enter the cell, wherein the parvovirus particle comprises:
a parvovirus capsid; and
the vector genome comprising in the 5′ to 3′ direction:
(i) a 5′ parvovirus terminal repeat;
(ii) a first heterologous nucleotide sequence;
(iii) a modified parvovirus terminal repeat such that resolution by Rep protein is reduced;
(iv) a separate heterologous nucleotide sequence; and
(v) a 3′ parvovirus terminal repeat,
wherein the first and second heterologous nucleotide sequences are essentially self-complementary and may form a hairpin structure that comprises the nucleic acid.
2. A method of administering a nucleic acid to a mammalian subject comprising administering to the mammalian subject a parvovirus particle comprising:
a parvovirus capsid; and
a vector genome comprising in the 5′ to 3′ direction:
(i) a 5′ parvovirus terminal repeat
(ii) a first heterologous nucleotide sequence;
(iii) a modified parvovirus terminal repeat such that resolution by Rep protein is reduced;
(iv) a separate heterologous nucleotide sequence; and
(v) a 3′ parvovirus terminal repeat,
wherein the first and second heterologous nucleotide sequences are essentially self-complementary and may form a hairpin structure that comprises the nucleic acid.
3. The method of claim 2 , wherein the parvovirus capsid is an adeno-associated virus (AAV) capsid.
4. The method of claim 2 , wherein the 5′ and 3′ parvovirus terminal repeats are 5′ and 3′ adeno-associated virus (AAV) terminal repeats.
5. The method of claim 2 , wherein the subject is a human subject.
6. The method of claim 2 , wherein the subject is a cancer patient or a tumor patient.
7. The method of claim 2 , wherein the parvovirus particle is administered by a route selected from the group consisting of oral, rectal, transmucosal, transdermal, inhalation, intravenous, subcutaneous, intradermal, intracranial, intramuscular, and intraarticular administration.
8. The method of claim 2 , wherein the parvovirus particle is administered to a site selected from the group consisting of a tumor, the brain, a skeletal muscle, the airway epithelium, the liver, and the eye.
9. The method of claim 2 , wherein a heterologous polypeptide is encoded by the vector genome.
10. The method of claim 9 , wherein the polypeptide is selected from the group consisting of an endostatin, an angiostatin, a superoxide dismutase, erythropoietin, Factor IX, and a monoclonal antibody.
11. The method of claim 2 , wherein said modified parvovirus terminal repeat is a parvovirus terminal repeat comprising an insertion, deletion or substitution in the nucleotide sequence of said modified parvovirus terminal repeat.
12. The method of claim 2 , wherein said modified parvovirus terminal repeat is a parvovirus terminal repeat comprising an insertion, deletion or substitution in the nucleotide sequence of the terminal resolution site (trs).
13. A method of administering a nucleic acid to a mammalian subject, comprising administering to the mammalian subject a parvovirus particle comprising:
(a) an adeno-associated virus (AAV) capsid; and
(b) a vector genome comprising in the 5′ to 3′ direction:
(i) a 5′ AAV terminal repeat;
(ii) a first heterologous nucleotide sequence;
(iii) a modified AAV terminal repeat such that resolution by Rep protein is reduced;
(iv) a separate heterologous nucleotide sequence; and
(v) a 3′ AAV terminal repeat;
wherein the first and second heterologous nucleotide sequences are essentially self-complementary and may form a hairpin structure that comprises the nucleic acid.
14. The method of claim 13 , wherein said modified AAV terminal repeat is an AAV terminal repeat comprising an insertion, deletion or substitution in the nucleotide sequence of said modified AAV terminal repeat.
15. The method of claim 13 , wherein said modified AAV terminal repeat is an AAV terminal repeat comprising an insertion, deletion or substitution in the nucleotide sequence of the terminal resolution site (trs).